Respiratory syncytial virus is common but it can be dangerous for some infants and young kids. Here's everything parents need ...

A major UK-led clinical trial has found that a treatment commonly used to help premature babies breathe offers no benefit for ...

Chicago, June 09, 2025 (GLOBE NEWSWIRE) -- The global respiratory syncytial virus treatment market valued at USD 2,387.2 million in 2024 and is projected to reach USD 8,332.5 million by 2033 ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Understanding the differences between colds, flu, and RSV can help in identifying the illness you're dealing with, the ...

The CDC's Advisory Committee on Immunization Practices (ACIP) has issued new vaccine recommendations affecting RSV and flu ...

Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections (ALRTIs) in children under five and poses a persistent threat to child health worldwide.

A medical panel appointed by Health Secretary Robert F. Kennedy Jr. voted Thursday to recommend a new antibody treatment ...

On day one of the highly anticipated first meeting of the CDC's newly formed vaccine advisory committee, members debated the ...

A new national guideline provides evidence-based recommendations for diagnosing, treating, and preventing pediatric ...

The U.S. Food and Drug Administration has approved Merck's Enflonsia, a treatment to prevent respiratory syncytial virus lower respiratory tract disease in newborns and infants. The company said ...